Cargando…

Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab

Background: Systemic agents in cancer treatment were often associated with possible infusion reactions (IRs). This study estimated the incidence of IRs requiring medical intervention and assessed the clinical and economic impacts of IRs in patients with colorectal cancer (CRC) treated with cetuximab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foley, K. A., Wang, P. F., Barber, B. L., Long, S. R., Bagalman, J. E., Wagner, V., Song, X., Zhao, Z.
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2010
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890318/ https://www.ncbi.nlm.nih.gov/pubmed/20100773 http://dx.doi.org/10.1093/annonc/mdp535

Ejemplares similares

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

High incidence of cetuximab-related infusion reactions in head and neck patients
por: Palomar Coloma, Virginia, et al.
Publicado: (2018)

Management of infusion reactions associated with cetuximab treatment: A case report
por: Ohshita, Naohiro, et al.
Publicado: (2017)

Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer
por: Song, Xue, et al.
Publicado: (2011)

PTEN status in advanced colorectal cancer treated with cetuximab
por: Negri, F V, et al.
Publicado: (2010)

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?
por: Merlano, Marco C, et al.
Publicado: (2018)

A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions
por: Maier, Sabine, et al.
Publicado: (2015)

Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer
por: Yokokawa, Hideyuki, et al.
Publicado: (2020)

Reply to Retrospective evaluation of cetuximab-related adverse events from claims databases—methodological concerns
por: Foley, K. A., et al.
Publicado: (2010)

Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?
por: Dupont, M, et al.
Publicado: (2022)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Severe Infusion Reactions to Cetuximab Occur within 1 h in Patients with Metastatic Colorectal Cancer: Results of a Nationwide, Multicenter, Prospective Registry Study of 2126 Patients in Japan
por: Yamaguchi, Kensei, et al.
Publicado: (2014)

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab
por: Xu, Yifan, et al.
Publicado: (2018)

Retrospective analysis of premedication, glucocorticosteroids, and H(1)-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer
por: Ikegawa, Kiwako, et al.
Publicado: (2017)

Evolving role of cetuximab in the treatment of colorectal cancer
por: Schuch, Gunter, et al.
Publicado: (2009)

Peripheral White Blood Cell Subsets in Metastatic Colorectal Cancer Patients Treated with Cetuximab: The Potential Clinical Relevance
por: Matić, Ivana Z., et al.
Publicado: (2018)

Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases
por: Sperling, Jens, et al.
Publicado: (2012)

Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis
por: Neyns, B., et al.
Publicado: (2008)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Right- and left-sided colorectal cancers respond differently to cetuximab
por: Wang, Feng, et al.
Publicado: (2015)

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
por: Tak, Eunyoung, et al.
Publicado: (2022)

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
por: Meyerhardt, Jeffrey A., et al.
Publicado: (2012)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
por: Baas, J. M., et al.
Publicado: (2015)

Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer
por: Zhou, Yuwen, et al.
Publicado: (2019)

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
por: Berger, Bernhard, et al.
Publicado: (2008)

Prospective practice survey of management of cetuximab-related skin reactions
por: Lugtenberg, R. T., et al.
Publicado: (2020)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
por: Lévi, Francis, et al.
Publicado: (2017)

Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
por: Putri, Septiara, et al.
Publicado: (2023)

Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer
por: Yu, Chaoran, et al.
Publicado: (2018)

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
por: Dahan, Laetitia, et al.
Publicado: (2011)

Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts
por: De Tursi, Michele, et al.
Publicado: (2017)

Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab
por: Baas, Jara, et al.
Publicado: (2018)

Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
por: Takada, Shinya, et al.
Publicado: (2018)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kq5ii0hkdvktnrjnl8ph06aouf